Galunisertib
Product Specifications
Product Name Alternative
LY2157299
UNSPSC Description
Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.
Target Antigen
TGF-β Receptor
Type
Reference compound
Related Pathways
TGF-beta/Smad
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/LY2157299.html
Purity
99.95
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=CC=CC(C2=NN3C(CCC3)=C2C4=CC=NC5=C4C=C(C=C5)C(N)=O)=N1
Molecular Weight
369.42
References & Citations
[1]Cong L, et al. Targeting the TGF-β receptor with kinase inhibitors for scleroderma therapy. Arch Pharm (Weinheim). 2014 Sep;347(9):609-15.|[2]Serova M, et al. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget. 2015 Aug 28;6(25):21614-27|[3]Bueno L, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer. 2008 Jan;44(1):142-50.|[4]Herbertz S, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther. 2015 Aug 10;9:4479-99.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-13226/Galunisertib-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-13226/Galunisertib-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
700874-72-2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
BNCB1897-500 500 µL
Anti-Caldesmon, HMW (h-Caldesmon) (Smooth Muscle Marker) (rCALD1/820), Biotin conjugate
Ask
View Details 